Despite the development of allogeneic stem-cell transplant (allo-SCT) and novel therapies, outcomes in patients with relapsed and/or refractory acute myeloid leukemia (AML) remain poor, especially for pediatric patients with relapsed and/or refractory AML (R/R-AML), which highlights the need for more effective therapies.
Over the past last decade, emerging immunotherapy and targeted therapies have been rapidly shaping the treatment landscape for R/R-AML, with the onset of immune checkpoint inhibitors (ICIs) and CAR-T in clinics for patients with hematologic malignancies. Immunotherapy and cell therapy have taken a new direction in hematologic cancer management, especially as combination therapies. Early-phase clinical trials of natural killer (NK) cells or chimeric antigen receptor (CAR)-T for R/R-AML showed complete remission (CR) or marked reduction of marrow blasts in a few enrolled patients, highlighting the potential effectiveness of immunotherapies in the treatment of R/R-AML.
Although the efficacy of these cutting-edge technologies is still under evaluation, and direct evidence of CAR T-cell treatment response from patients with R/R-AML remains limited, immunotherapy and cell therapy still hold immeasurable potential in the management of R/R-AML.
In this Research Topic, we would like to gather new insights into the immunobiology of myeloid neoplasm. We aim to promote the development of immunotherapy for AML. We welcome submissions of Original Research, Clinical Trial, Methods, Case Report, Systematic Review, Review, and Mini-Review articles focusing on the following sub-topics:
1. Identification or validation of novel immunotherapeutic targets for R/R-AML
2. Safety profile, including reports of immunotherapy and cell therapy adverse events in clinical application
3. Novel design and application of CAR-T, CAR-NK, or CAR-Macrophages for patients with R/R-AML
4. Promotion of novel biomaterials and nanotechnology for immunotherapy or cell therapy in R/R-AML
5. Characterization of the tumor immune microenvironment in the bone marrow and AML cell behavior.
6. Novel combination therapies programs for R/R-AML
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of the scope for this section and will not be accepted as part of this Research Topic.
Despite the development of allogeneic stem-cell transplant (allo-SCT) and novel therapies, outcomes in patients with relapsed and/or refractory acute myeloid leukemia (AML) remain poor, especially for pediatric patients with relapsed and/or refractory AML (R/R-AML), which highlights the need for more effective therapies.
Over the past last decade, emerging immunotherapy and targeted therapies have been rapidly shaping the treatment landscape for R/R-AML, with the onset of immune checkpoint inhibitors (ICIs) and CAR-T in clinics for patients with hematologic malignancies. Immunotherapy and cell therapy have taken a new direction in hematologic cancer management, especially as combination therapies. Early-phase clinical trials of natural killer (NK) cells or chimeric antigen receptor (CAR)-T for R/R-AML showed complete remission (CR) or marked reduction of marrow blasts in a few enrolled patients, highlighting the potential effectiveness of immunotherapies in the treatment of R/R-AML.
Although the efficacy of these cutting-edge technologies is still under evaluation, and direct evidence of CAR T-cell treatment response from patients with R/R-AML remains limited, immunotherapy and cell therapy still hold immeasurable potential in the management of R/R-AML.
In this Research Topic, we would like to gather new insights into the immunobiology of myeloid neoplasm. We aim to promote the development of immunotherapy for AML. We welcome submissions of Original Research, Clinical Trial, Methods, Case Report, Systematic Review, Review, and Mini-Review articles focusing on the following sub-topics:
1. Identification or validation of novel immunotherapeutic targets for R/R-AML
2. Safety profile, including reports of immunotherapy and cell therapy adverse events in clinical application
3. Novel design and application of CAR-T, CAR-NK, or CAR-Macrophages for patients with R/R-AML
4. Promotion of novel biomaterials and nanotechnology for immunotherapy or cell therapy in R/R-AML
5. Characterization of the tumor immune microenvironment in the bone marrow and AML cell behavior.
6. Novel combination therapies programs for R/R-AML
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of the scope for this section and will not be accepted as part of this Research Topic.